Quick Answer
Autolus Therapeutics plc reported Total Assets of $589.07 million for the year ending 2025.
- Autolus Therapeutics plc showed a decrease of -24.7% in Total Assets from 2024 to 2025.
- This data is from Autolus Therapeutics plc's annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2017 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: $901.44 million | Q2 2024: $853.62 million | Q3 2024: $827.49 million | Q1 2025: $746.34 million | Q2 2025: $720.98 million | Q3 2025: $661.95 million.
- Over the full 17 years of available data (2017 to 2025), Autolus Therapeutics plc's Total Assets has grown by 296.2%.
- Historical annual values: Fiscal year 2025: $589.07 million | Fiscal year 2024: $782.73 million | Fiscal year 2023: $375.38 million | Fiscal year 2023: $406.10 million | Fiscal year 2023: $450.99 million | Fiscal year 2023: $459.97 million | Fiscal year 2022: $490.27 million | Fiscal year 2022: $263.83 million | Fiscal year 2022: $313.98 million | Fiscal year 2022: $363.99 million | Fiscal year 2021: $405.56 million | Fiscal year 2020: $294.24 million | Fiscal year 2019: $303.53 million | Fiscal year 2018: $254.21 million | Fiscal year 2018: $273.21 million | Fiscal year 2017: $142.72 million | Fiscal year 2017: $148.66 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: